MedTrace Logo

N-acetyl-cysteine (NAC) and Kidney Graft Function

NCT00998972 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2011-07-12

No results posted yet for this study

Summary

The goal of this study is to evaluate the effect of N-acetyl-cysteine (NAC) administration in organ donors on the kidney graft function of recipients.

Conditions

  • Brain Death
  • Chronic Renal Insufficiency

Interventions

DRUG

N-acetylcysteine

600 mg intravenous before and 2 hours after cerebral arteriography

Sponsors & Collaborators

  • Institut d'Anesthesiologie des Alpes Maritimes

    lead OTHER

Principal Investigators

  • Carole R Ichai, MD, PhD · Service de Reanimation Medicochirurgical. CHU de Nice

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2010-12-31
Completion
2011-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00998972 on ClinicalTrials.gov